Gamboa P M, García-Avilés M C, Urrutia I, Antépara I, Esparza R, Sanz M L
Servicio de Alergia, Hospital de Basurto, Bilbao, Spain.
J Investig Allergol Clin Immunol. 2004;14(4):278-83.
New in vitro diagnostic methods for IgE-mediated drug allergic reactions, such as basophil activation test and antigen specific sulfidoleukotriene test, have proven their usefulness in patients with positive skin tests.
To assess the usefulness of basophil activation test and antigen specific sulfidoleukotriene test in the diagnosis of patients with IgE-mediated allergy to Betalactam antibiotics and negative skin tests.
The 23 patients included in the study underwent basophil activation test, antigen specific sulfidoleukotriene test and specific IgE. The patients were classified into three groups.
patients with positive specific IgE.
patients with a unique immediate reaction to Betalactams, negative specific IgE and positive oral provocation tests. And Group C: patients with at least two immediate reactions induced by Betalactams and negative specific IgE.
The sensitivity/specificity of the different tests are: basophil activation test 39.1 %/93.3%, antigen specific sulfidoleukotriene test 22.7%/83.3%, specific IgE 21.7%/86.7%. The joint use of the three tests allows diagnosis of 60.9% of the patients.
In vitro diagnostic tests, especially basophil activation test, are very important tools in the diagnosis of patients with IgE-mediated allergy to Betalactams and negative skin tests, avoiding performance of potentially dangerous oral provocation tests in a high percentage of cases.
用于免疫球蛋白E(IgE)介导的药物过敏反应的新型体外诊断方法,如嗜碱性粒细胞活化试验和抗原特异性硫代白三烯试验,已在皮肤试验阳性的患者中证明了其有效性。
评估嗜碱性粒细胞活化试验和抗原特异性硫代白三烯试验在诊断IgE介导的对β-内酰胺类抗生素过敏且皮肤试验阴性的患者中的有效性。
纳入研究的23例患者接受了嗜碱性粒细胞活化试验、抗原特异性硫代白三烯试验和特异性IgE检测。患者被分为三组。
A组:特异性IgE阳性的患者。
B组:对β-内酰胺类药物有独特速发型反应、特异性IgE阴性且口服激发试验阳性的患者。
C组:至少有两次由β-内酰胺类药物诱发的速发型反应且特异性IgE阴性的患者。
不同检测方法的敏感性/特异性分别为:嗜碱性粒细胞活化试验39.1%/93.3%,抗原特异性硫代白三烯试验22.7%/83.3%,特异性IgE 21.7%/86.7%。联合使用这三种检测方法可诊断60.9%的患者。
体外诊断试验,尤其是嗜碱性粒细胞活化试验,是诊断IgE介导的对β-内酰胺类药物过敏且皮肤试验阴性的患者的重要工具,可在很大比例的病例中避免进行潜在危险的口服激发试验。